Widespread Repression of Gene Expression in Cancer by a Wnt/β-Catenin/MAPK Pathway.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33203702.
- Also identified by DOI 10.1158/0008-5472.CAN-20-2129.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Aberrant Wnt signaling drives a number of cancers through regulation of diverse downstream pathways. Wnt/β-catenin signaling achieves this in part by increasing the expression of proto-oncogenes such as <i>MYC</i> and cyclins. However, global assessment of the Wnt-regulated transcriptome <i>in vivo</i> in genetically distinct cancers demonstrates that Wnt signaling suppresses the expression of as many genes as it activates. In this study, we examined the set of genes that are upregulated upon inhibition of Wnt signaling in Wnt-addicted pancreatic and colorectal cancer models. Decreasing Wnt signaling led to a marked increase in gene expression by activating ERK and JNK; these changes in gene expression could be mitigated in part by concurrent inhibition of MEK. These findings demonstrate that increased Wnt signaling in cancer represses MAPK activity, preventing RAS-mediated senescence while allowing cancer cells to proliferate. These results shift the paradigm from Wnt/β-catenin primarily as an activator of transcription to a more nuanced view where Wnt/β-catenin signaling drives both widespread gene repression and activation. SIGNIFICANCE: These findings show that Wnt/β-catenin signaling causes widespread gene repression via inhibition of MAPK signaling, thus fine tuning the RAS-MAPK pathway to optimize proliferation in cancer.
Medical subject headings
- Biomarkers, Tumor
- Carcinoma, Pancreatic Ductal
- Gene Expression Regulation, Neoplastic
- Mitogen-Activated Protein Kinases
- Pancreatic Neoplasms
- Wnt1 Protein
- beta Catenin